If You Invested $1,000 in Fulcrum Therapeutics (FULC)
This article analyzes the historical performance of investing $1,000 in Fulcrum Therapeutics (FULC) over different periods, revealing significant losses for investors in recent years. It also provides a detailed overview of Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focusing on genetically defined rare diseases, with its lead program, pociredir, targeting sickle cell disease. The company's strategy involves modulating gene expression, and pociredir has received FDA Fast Track and Orphan Drug designations.
Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike
Fulcrum Therapeutics director Sonja Banks has been granted 32,000 stock options with an exercise price of $3.66 per share, expiring on June 29, 2036. The options will vest on the first anniversary of the June 30, 2026 grant date or earlier, subject to continued service. This transaction is a compensation grant and not an open-market purchase or sale.
Fulcrum Therapeutics (FULC) director granted 32,000 stock options at $3.66 strike
Fulcrum Therapeutics director Kate Haviland was granted 32,000 stock options at an exercise price of $3.66 per share. This grant, effective June 30, 2026, is scheduled to vest fully on the first anniversary or prior to the first annual stockholders' meeting, assuming continued service. Following this transaction, Haviland directly holds options for 32,000 shares.
Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike
Fulcrum Therapeutics director James A. Geraghty was granted 32,000 stock options with an exercise price of $3.66 per share, set to expire on June 29, 2036. The options will vest on the first anniversary of the June 30, 2026 grant date, or sooner, subject to his continued service. This transaction is considered a routine equity grant for a director.
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity
Fulcrum Therapeutics, Inc. director Alan Ezekowitz was granted a stock option for 32,000 shares of common stock at an exercise price of $3.66 per share, expiring on June 29, 2036. The option is set to vest in full on the first anniversary of the June 30, 2026 grant date or earlier, contingent on his continued service. This transaction is categorized as a grant rather than an open-market purchase, increasing his reported derivative holdings to 32,000 shares for this option.
Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66
Fulcrum Therapeutics director Robert J. Gould was granted 32,000 stock options with an exercise price of $3.66 per share, expiring on June 29, 2036. The options are scheduled to vest on the first anniversary of the June 30, 2026 grant date or earlier, contingent on his continued service. This compensation-related transaction is detailed in an SEC Form 4 filing, indicating it was not an open-market purchase.
Fulcrum Therapeutics (FULC) director awarded 32,000 stock options
Fulcrum Therapeutics director Katina Dorton was granted 32,000 stock options with an exercise price of $3.66 per share, expiring on June 29, 2036. This grant, made at no upfront cost, is set to vest fully on the first anniversary of the June 30, 2026, date or earlier, immediately before the first annual stockholder meeting after the grant date, contingent on her continued service. Following this transaction, Dorton directly holds 32,000 stock options.
Fulcrum Therapeutics | 8-K: Current report
This article is a current report filed by Fulcrum Therapeutics, indicating an 8-K filing. The content itself explicitly states "Document," suggesting the actual report itself is missing or was unable to be processed, and this entry acts as a placeholder for the filing notification.
FULC - Fulcrum Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings information for Fulcrum Therapeutics Inc. It includes comprehensive financial data, performance metrics, and key statistics for the company as of July 1, 2026. The report details market capitalization, income, sales, share information, and various financial ratios, alongside insider and institutional ownership data.
Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan
Fulcrum Therapeutics director Alan Ezekowitz sold 18,000 shares of common stock at a weighted average price of $3.6452 per share through a pre-arranged Rule 10b5-1 trading plan. This transaction, valued at approximately $65,600, leaves Ezekowitz with 10,927 shares directly held. The sales occurred on June 26, 2026, within a price range of $3.555 to $3.82.
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2000 Growth Benchmark
Fulcrum Therapeutics, Inc. (NasdaqGM:FULC) has been dropped from the Russell 2000 Growth Benchmark. This news comes amidst other recent adjustments including its removal from the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell Microcap Growth Index, and Russell 3000 Growth benchmarks. The company has also faced a series of downgrades from analysts and is undergoing a restructuring plan.
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000E Growth Benchmark
Fulcrum Therapeutics, Inc. (NasdaqGM:FULC) has been dropped from the Russell 3000E Growth Benchmark. This news comes amidst a series of other recent downgrades from various financial analysts and a restructuring plan announced earlier in June. The company is a clinical-stage biopharmaceutical firm focusing on genetically defined rare diseases.
Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC
The article provides the "Price to book forward" for Fulcrum Therapeutics, Inc. (NASDAQ: FULC). It is a brief financial data point from TradingView, which also lists other market information, company financials, and community features related to the stock. The content itself seems to be a data element embedded within a larger financial platform interface rather than a full analytical article.
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit
Fulcrum Therapeutics' modeled fair value has decreased by 71% to approximately US$5.43 after the discontinuation of pociredir and class-wide PRC2 safety concerns. Analysts are now focusing on the company's cash position and potential strategic alternatives, leading to significantly lower price targets from several firms. The company's narrative has shifted from late-stage development to asset value and corporate actions, with some research houses suspending ratings due to limited visibility on future value creation.
[144] Fulcrum Therapeutics, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Fulcrum Therapeutics, Inc. (FULC) on June 26, 2026. The filing indicates a proposed sale of 18,000 shares of common stock with an aggregate market value of $64,980.00, acquired on March 15, 2017, through Restricted Stock Units. The sale is to be brokered by Morgan Stanley Smith Barney LLC.
EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC)
EcoR1 Capital, LLC and Oleg Nodelman have disclosed a 9.0% beneficial ownership stake in Fulcrum Therapeutics (NASDAQ: FULC), while EcoR1 Capital Fund Qualified, L.P. reports an 8.4% stake. These holdings represent significant passive investments, with percentages calculated based on 66,633,321 shares outstanding as of April 20, 2026. The filing indicates shared voting and dispositive power but explicitly states these stakes are for investment purposes and not intended to change or influence company control.
Fulcrum Therapeutics (FULC) details 2026 stockholder voting on directors and key proposals
Fulcrum Therapeutics (FULC) has reported the voting results from its 2026 annual meeting of stockholders held on June 24, 2026. Stockholders elected Sonja Banks, Alan Ezekowitz, and Colin Hill as Class I directors for three-year terms. Additionally, stockholders approved, on a non-binding advisory basis, the compensation of executive officers and ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
Fulcrum Therapeutics Inc (FULC) Institutional Confidence
Fulcrum Therapeutics Inc. (FULC) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The total institutional shareholding proportion is 104.53%, reflecting a quarter-over-quarter decrease of 26.94%. Steven Cohen is the largest institutional shareholder, holding 2.35M shares, which represents 3.12% of the company's outstanding shares.
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program due to FDA concerns about its benefit-risk profile. The FDA concluded that all PRC2 inhibitors carry an equivalent malignancy risk, leading to no viable regulatory path for pociredir and a significant drop in Fulcrum Therapeutics' stock price. Investors who suffered losses are encouraged to contact Kaplan Fox for more information on the investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Fulcrum Therapeutics, Inc. (FULC) following the company's disclosure of FDA concerns regarding a potential malignancy risk associated with PRC2 inhibition. Fulcrum announced it would discontinue the development of its lead candidate, pociredir, and initiate a strategic review, leading to a significant drop in its stock price. The law firm is encouraging investors who purchased Fulcrum securities to join the investigation.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's benefit-risk profile due to a high rate of secondary hematologic malignancies associated with a similar PRC2 inhibitor. Following this news, Fulcrum Therapeutics' stock price dropped over 51%.
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). This investigation follows the company's announcement of discontinuing its pociredir program for sickle cell disease due to heightened FDA concerns regarding the drug's benefit-risk profile and malignancy risk. As a result, Fulcrum Therapeutics' stock price declined significantly.
Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Fulcrum Therapeutics Inc (FULC) has an earnings forecast score of 5.78, ranking 337th in the Biotechnology & Medical Research industry. Analysts have an average price target of $20.00, with a range of $5.00 to $25.00. Based on ratings from 9 analysts, the consensus is to "Hold" FULC stock.
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's benefit-risk profile due to a high rate of secondary hematologic malignancies associated with another PRC2 inhibitor. The news led to a 51.09% drop in Fulcrum Therapeutics' stock price.
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) after the company disclosed concerns from the U.S. FDA regarding a malignancy risk with its lead candidate, pociredir, leading to its discontinuation and a significant stock price drop. Investors who purchased Fulcrum securities are encouraged to contact the firm to learn more and assist with the investigation. The firm operates on a contingency fee basis for class actions.
Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the major shareholder structure and institutional holdings of Fulcrum Therapeutics Inc (FULC). It lists the top individual shareholders and classifies shareholders by type, such as hedge funds and investment advisors. The report also provides a historical overview of institutional shareholding, showing changes in the number of institutions, shares held, and proportional ownership over various reporting periods.
FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan F
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program due to FDA concerns about its benefit-risk profile and malignancy risk. Following this announcement on June 1, 2026, Fulcrum Therapeutics' stock price dropped over 51%. Investors who experienced losses are encouraged to contact Kaplan Fox & Kilsheimer LLP for further information regarding the investigation.
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) securities. This investigation follows Fulcrum's disclosure that the FDA raised concerns about a potential malignancy risk with PRC2 inhibition, leading the company to discontinue development of its lead candidate, pociredir, and initiate a strategic review. Shareholders are encouraged to contact the firm to learn more and assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (FULC) following the company's disclosure of FDA concerns regarding malignancy risk associated with PRC2 inhibition. Fulcrum announced the discontinuation of its lead candidate, pociredir, and a strategic business review, causing its stock price to drop. The law firm is encouraging affected investors to visit its website for more information and to assist in the investigation.
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Fulcrum Therapeutics, Inc. (FULC) on behalf of investors. This investigation follows Fulcrum's disclosure of FDA concerns about a potential malignancy risk associated with PRC2 inhibition, leading the company to discontinue development of its lead candidate, pociredir, and initiate a strategic review. The firm encourages affected stockholders to contact them for more information.
Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart
Fulcrum Therapeutics has implemented special retention and change-in-control protections for its remaining leadership following a major restructuring tied to discontinuing the development of pociredir for sickle cell disease. CEO Alex C. Sapir, Chief Legal Officer Curtis Oltmans, and Chief Financial Officer Alan Musso are among those receiving significant cash retention bonuses, payable upon a qualifying change in control or termination without cause and completion of transitional duties. Concurrently, the company announced the mutual agreement for Vice President of Finance, Greg Tourangeau, to depart, with Fulcrum clarifying that his exit is not related to any financial reporting disagreements.
Tang entities report 5,451,800‑share stake in Fulcrum (FULC)
Tang Capital Management and affiliated entities have reported a combined stake of 5,451,800 shares, representing 8.2% of Fulcrum Therapeutics (FULC) common stock. This beneficial ownership involves shared voting and dispositive power among the Tang group, as detailed in a Schedule 13G SEC filing. The percentage is based on 66,633,321 shares outstanding as of April 20, 2026.
Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the discontinuation of its pociredir program for sickle cell disease. The decision came after FDA concerns regarding the drug's benefit-risk profile, particularly an unexpectedly high rate of secondary hematologic malignancies associated with another PRC2 inhibitor. This news led to a 51.09% decline in Fulcrum Therapeutics' stock price.
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky, LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after its shares dropped by approximately 50% following a disclosure that the FDA raised safety concerns regarding PRC2 inhibition. The company subsequently discontinued its lead sickle cell disease candidate, pociredir, which is a PRC2-targeting agent, and initiated a strategic review. The investigation focuses on whether Fulcrum made misleading statements about pociredir's safety profile and regulatory prospects.
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. following a significant stock price decline. The decline occurred after Fulcrum Therapeutics announced the discontinuation of its pociredir program for sickle cell disease due to FDA concerns about malignancy risk, leading to no viable regulatory path forward. Investors who suffered losses are encouraged to contact Kaplan Fox for more information regarding this investigation.
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (FULC) after the company announced it was discontinuing the development of its lead candidate, pociredir, due to FDA concerns about a potential malignancy risk. This news led to a drop in Fulcrum's stock price. The firm is encouraging affected investors to contact them to learn more about the investigation.
Fulcrum plunges after discontinuing lead program
Fulcrum Therapeutics announced it is discontinuing the development of its lead program, losmapimod, for facioscapulohumeral muscular dystrophy (FSHD) after it failed to meet its primary endpoint in a Phase 3 trial. This decision led to a significant drop in its stock price and a strategic pipeline reprioritization, focusing on other early-stage assets. The company will also implement a cost-cutting plan, including reducing its workforce.
Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)
Levi & Korsinsky has initiated an investigation into the officers and directors of Fulcrum Therapeutics, Inc. (FULC) following a significant stock collapse. The investigation stems from the company's discontinuation of its pociredir program due to FDA safety concerns, despite prior CEO statements about its Phase III future and existing long-term financial commitments like a $25.1 million facilities lease. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to discuss potential securities law violations.
What's Going On With Fulcrum Therapeutics Stock On Thursday?
Fulcrum Therapeutics stock experienced volatility on Thursday after the company discontinued its lead experimental sickle cell disease drug, pociredir, due to FDA concerns about malignancy risks. This decision followed FDA interactions highlighting risks similar to another PRC2 inhibitor, Tazverik, despite Fulcrum's arguments about mechanistic differences. The company is now exploring strategic alternatives like a merger or acquisition, while its stock shows bearish technical indicators and has received several analyst downgrades.
Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks
Fulcrum Therapeutics has discontinued its clinical-stage program for pociredir, a sickle cell disease treatment, after the FDA raised concerns about potential malignancy risks associated with its mechanism of action. This decision follows the withdrawal of Ipsen’s similar drug, Tazverik, and leaves Fulcrum with no viable regulatory path forward for pociredir. The company is now exploring strategic alternatives and plans to significantly reduce operating expenses.
Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives
Fulcrum Therapeutics is laying off 85% of its workforce, notifying employees on Thursday. The Cambridge biotech has enlisted Leerink Partners to explore strategic alternatives such as a merger or acquisition. This move comes as the company navigates its future options.
Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)
Levi & Korsinsky, LLP has announced an investigation into potential securities claims against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant 50% stock drop. This plunge occurred after Fulcrum disclosed that the FDA raised class-wide safety concerns about PRC2-targeting agents, leading to the discontinuation of its lead sickle cell candidate, pociredir. The investigation aims to determine if the company failed to adequately disclose material risks to investors prior to this announcement.
A Look At Fulcrum Therapeutics (FULC) Valuation After Halting Pociredir And Launching A Broad Review
Fulcrum Therapeutics (FULC) is undergoing a significant re-evaluation after halting its sickle cell drug pociredir due to FDA concerns, leading to a 52.5% drop in share price over seven days. While some narratives suggest the stock is undervalued at $3.22, with a fair value estimate of $19 based on potential future revenue from successful trials, a discounted cash flow model suggests it might be overvalued at $2.19. Investors are now left to weigh the potential for a reset buying opportunity against inherent risks and the reliability of different valuation methodologies.
Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review
Fulcrum Therapeutics is undergoing a major restructuring, reducing its workforce by 85% (from 57 to 9 employees) and incurring $4.2 million in related charges, primarily due to the discontinuation of its sickle cell disease program, pociredir. The company has engaged Leerink Partners LLC to explore strategic alternatives, including potential mergers, acquisitions, or asset sales, to maximize stockholder value. However, there is no guarantee that any transaction will occur as a result of this review.
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud
Levi & Korsinsky is investigating Fulcrum Therapeutics, Inc. (FULC) for potential securities fraud after its stock plunged approximately 50% on June 1, 2026. This drop followed the company's disclosure of FDA safety concerns related to its PRC2 inhibitor drug class, leading to the discontinuation of its lead sickle-cell candidate, pociredir. The investigation will examine whether Fulcrum adequately disclosed material risks to investors prior to this significant market value loss.
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring
Fulcrum Therapeutics (FULC) has shown sharp volatility after discontinuing its lead sickle cell drug, pociredir, and undergoing a major restructuring. While analysts suggest the stock is undervalued at $3.37 with a fair value of $19 based on future growth, Simply Wall St's DCF model indicates it might be trading above its estimated future cash flow value of $2.19. Investors are advised to carefully consider both views and potential risks.
FULC stock crashes as cancer risk forces its only drug program's end
FULC stock has crashed after the company was forced to end its only drug program due to an increased risk of cancer. This decision significantly impacts the company's future prospects as it now lacks a primary product in development.
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations
SueWallSt is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations after the company's stock dropped approximately 50% following an FDA disclosure regarding class-wide safety concerns for PRC2-targeting agents, which led to the discontinuation of its lead candidate, pociredir. The investigation focuses on whether Fulcrum made misleading statements concerning insider trading disclosures, financial commitments, and the status of its pociredir program. Shareholders who suffered losses are encouraged to contact SueWallSt for a free evaluation.
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations
SueWallSt is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for possible securities law violations after the company's stock dropped approximately 50% following an FDA disclosure regarding class-wide safety concerns about PRC2-targeting agents, leading Fulcrum to discontinue its lead candidate pociredir. The investigation aims to determine if Fulcrum made misleading statements regarding insider trading disclosures, financial commitments, and the status of its pociredir program. Investors who suffered losses are encouraged to contact SueWallSt for a free, no-obligation evaluation.
Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options
Fulcrum Therapeutics (FULC) saw its stock drop 53.6% after announcing the discontinuation of its lead investigational drug, pociredir, due to FDA concerns about malignancy risks. The company is now exploring strategic options such as mergers or acquisitions and implementing cost-cutting measures to preserve its cash reserves. This shifts the investment focus from pociredir's potential to the successful execution of its strategic review and the value of its remaining assets and cash.
